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Background: The prevalence of delirium in intensive care unit (ICU) patients is high. Delirium has been associated
with morbidity and mortality including more ventilator days, longer ICU stay, increased long-term mortality and
cognitive impairment. Thus, the burden of delirium for patients, relatives and societies is considerable.
Today, reviews of randomised clinical trials are produced in large scales sometimes making it difficult to get an
overview of the available evidence. A preliminary search identified several reviews investigating the effects of
pharmacological interventions for the management and prevention of delirium in ICU patients. The conclusions of
the reviews showed conflicting results. Despite this unclear evidence, antipsychotics, in particular, haloperidol is
often the recommended pharmacological intervention for delirium in ICU patients.
The objective of this overview of reviews is to critically assess the evidence of reviews of randomised clinical trials
on the effect of pharmacological management and prevention of delirium in ICU patients.
Methods/design: We will search for reviews in the following databases: Cochrane Library, MEDLINE, EMBASE,
Science Citation Index, BIOSIS, Cumulative Index to Nursing and Allied Health Literature, Latin American and
Caribbean Health Sciences Literature, and Allied and Complementary Medicine Database.
Two authors will independently select references for inclusion using Covidence, extract data and assess the
methodological quality of the included systematic reviews using the ROBIS tool. Any disagreement will be resolved
by consensus.
We will present the data as a narrative synthesis and summarise the main results of the included reviews. In
addition, we will present an overview of the bias risk assessment of the systematic reviews.
Discussion: Results of this overview may establish a way forward to find and update or to design a high quality
systematic review assessing the effects of the most promising pharmacological intervention for delirium in ICU
patients.
Systematic review registration: PROSPERO - CRD42016046628.
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Description of the condition
Delirium is a complex acute organic syndrome charac-
terised by a reduced ability to focus, sustain, or shift at-
tention, and either a change in cognition (memory
deficits, disorientation, or language disturbance) or the
development of a perceptual disturbance (hallucinations
or delusions) [1]. The pathophysiology of delirium is
superficially understood, and the mechanisms involved
are likely to be multiple [2, 3]. Delirium has been classi-
fied into motoric subtypes: (1) hypoactive delirium (pure
lethargy, withdrawal, flat affect, apathy and decreased re-
sponsiveness), (2) hyperactive delirium (agitation, rest-
lessness, attempting to remove catheters and emotional
lability), and (3) a mixed form delirium (fluctuation be-
tween hypoactive and hyperactive delirium) [4].
The prevalence of delirium is highest in hospitalised
older individuals and varies depending on the patient
characteristics, setting of care, and sensitivity of the de-
tection method. In the community, the overall preva-
lence of delirium is low (1 to 2%) but increases with age,
rising to 14% in individuals older than 85 years [5]. In
nursing homes and residential homes, the prevalence of
delirium is 8 to 9% [6]. At the time of hospital admis-
sion, the prevalence of delirium is an estimated 14 to
24% and the incidence 6 to 56% [7]. Delirium occurs in
9 to 87% of individuals postoperatively [8], in 40 to 60%
of the spontaneously breathing patients in intensive care,
in 60 to 89% of the mechanically ventilated patients in
intensive care [9], and up to 83% of all individuals at the
end of life [10].
Delirium is increasingly being recognised as a sig-
nificant contributor to the morbidity and mortality of
the intensive care unit (ICU) patients. Studies have
shown an increase in total ventilator days, ICU length
of stay, and long-term cognitive impairment [11, 12].
Pandharipande et al. [11] followed 821 surgical and
medical ICU patients and found that longer duration
of delirium was an independent risk factor for worse
global cognition scores at both 3 and 12 months after
discharge. Ely et al. [12] evaluated a smaller cohort of
224 ICU patients, and their results showed that delir-
ium was independently associated with 3.2 (95% Cl
1.4–7.7; P = .008) increased risk of 6-month mortality.
Contrary to this, in a larger cohort of 1112 ICU
patients, Klouwenberg et al. [13] did not find an
association between delirium and mortality after adjusting
for changes in disease severity before the onset of delir-
ium. Delirium complicates hospital stay for at least 20% of
the 12.5 million patients 65 years of age or older who are
hospitalised each year and increases hospital costs by
$2500 per patient. An estimated $6.9 billion of medical
hospital expenditures are attributable to delirium [5].
Substantial additional costs accumulate after hospitaldischarge because of the need for institutionalisation and
rehabilitation services. In the ICU, within the mechanic-
ally ventilated patients, delirium has been associated with
39% higher intensive care costs and 31% higher hospital
costs [14].
Different tools exist for the assessment of delirium in
the ICU. The Confusion Assessment Method for the
ICU (CAM-ICU) and the Intensive Care Delirium
Screening Checklist (ICDSC) are often used [15]. Studies
have indicated that delirium might be undetected in
more than 65% of the ICU patients when comparing
clinical identification of the presence of delirium to iden-
tification by the CAM-ICU or ICDSC scores [16, 17].
Hypoactive and mixed form delirium are the most com-
mon within the ICU patients [18, 19], and hypoactive
delirium has been suggested to be more deleterious than
the mixed form with worse outcomes and more long-
term harmful effects [4].
Description of the interventions
Abnormalities in cerebral oxidative metabolism, direct
neurotoxic effects of inflammatory cytokine alterations in
neurotransmitters (e.g. cholinergic, dopaminergic, seroto-
nergic), and gamma-aminobutyric pathways are all be-
lieved to be involved in the pathophysiology of delirium
[20]. Pharmacological interventions for delirium have fo-
cused on alterations in neurotransmitter pathways, in par-
ticular, dopaminergic and cholinergic pathways.
Several pharmacological strategies for delirium in the
ICU patients have been investigated:
1. Antipsychotics (both typical antipsychotics e.g.
haloperidol and atypical antipsychotics e.g.
olanzapine, quetiapine, risperidone, aripiprazol,
and ziprasidone)
2. Sedatives (e.g. benzodiazepines (midazolam,
lorazepam, diazepam), propofol, and
dexmedetomidine (alpha-2-antagonist))
3. Cholinesterase inhibitors (rivastigmine)
4. Opioids (e.g. morphine)
5. Melatonine and melatonine antagonists (e.g. ramelteon)
Guidelines and recommendations
Examples of guidelines and recommendations for delir-
ium in the ICU patients:
 The Society of Critical Care Medicine does not
recommend haloperidol for the management of
delirium due to lack of evidence, and rivastigmine
is also not recommended due to an increased risk
of torsades de pointes. Dexmedetomidine rather
than benzodiazepine is recommended for sedation
to reduce delirium in patients when the delirious
symptoms are unrelated to alcohol and
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patients is recommended to reduce incidence and
duration of delirium. The Society of Critical Care
Medicine recommends not using pharmacologic
delirium prevention protocols (including the use
of haloperidol, atypical antipsychotics and
dexmedetomidine) [21].
 The Intensive Care Society in the UK recommends
management of delirium with haloperidol, where
no organic cause can be identified and treated.
Olanzapine may be used as an alternative to
haloperidol. Chlorpromazine, risperidone, and
benzodiazepines are not recommended. Non-
pharmacological interventions for the prevention
of delirium are recommended. These interventions
include providing psychological support and
orientation (communication), stable environment
(lights, noise, temperature), maintaining competences
(e.g. correct sensory impairments, maintain activity
level), and removing potential organic drivers by
identifying and treating organic causes [22].
 The German guidelines for the management of
analgesia, sedation and delirium in intensive care
recommend management of delirium with
haloperidol, risperidone or olanzapine. Low-dose
haloperidol may be used prophylactically in geriatric
delirious patients [23].
 The Danish Society of Anaesthesiology and
Intensive Care states that for the management of
manifest delirium, it is a medical judgement
whether a pharmacological drug should be given,
even though it is noted that no evidence for
using pharmacological management exists. In
these circumstances, olanzapine or haloperidol
may be administered. Benzodiazepines may be
added if the patient is still agitated and sedation
with dexmedetomidine may be administered as a
last resort. In the recommendations by The
Danish Society of Anaesthesiology and Intensive
Care, it is mentioned that prophylactic-administered
haloperidol and ziprasidone does probably not reduce
the duration of delirium in mechanically ventilated
patients, but a precise advice against the use is not
given [24].
For delirium, in general, haloperidol is recommended
for the management of delirium patients with severe agi-
tation or those who are considered a risk to themselves
or to others. Prevention strategies do not include
prophylactic medication [1, 25–27].
How the interventions might work
Given the multiple mechanisms possibly resulting in the
development of delirium, a range of pharmacologicaldrugs have been studied. These different drugs target
the suspected neurotransmitter or receptor imbalances,
which may cause the distressing cognitive symptoms,
hallucinations, risky physical behaviour, etc.
In the following, we describe the theoretical thera-
peutic rationale for each type of drug.
Antipsychotics (dopaminergic pathway)
The therapeutic effects of antipsychotics in delirium
may be mediated via a number of different mechanisms
that include sedative or anxiolytic effects, antipsychotic
actions, or direct effects upon the proposed core neuro-
chemical disturbances of delirium [28].
Sedatives
The benzodiazepines midazolam and lorazepam (and to
a lesser extent, diazepam), propofol and dexmedetomi-
dine are the commonly used sedatives within the ICU
[29]. The opioid remifentanil is also used because of its
sedative effects. Benzodiazepines may act through g-
aminobutyric acid type A (GABAA) receptors, as in part
does propofol, whereas dexmedetomidine is an a2-
adrenoceptor agonist, and remifentanil is a μ-opioid re-
ceptor agonist [3].
Cholinesterase inhibitors
Impaired cholinergic neurotransmission seems to have
an important role in the development of delirium. In pa-
tients with delirium, serum anticholinergic activity has
been found to be increased [30] and, particularly in eld-
erly patients, drugs with anticholinergic effects can cause
delirium [31].
Opioids
Unrelieved pain induces stress responses characterised
by tachycardia, increased myocardial oxygen consump-
tion, hyper-coagulability, immunosuppression, and per-
sistent catabolism. Ensuring adequate pain control might
be essential. At low doses, opioids provide analgesia and
in high doses, they provide anxiolysis and sedation [32].
The mechanism of action of pain management with
ketamine, a N-methyl-D-aspartate receptor blocker, is
not well understood.
Melatonine
Melatonine is a hormone normally produced in the pin-
eal gland. It is assumed to help regulate sleep-wake cy-
cles or the circadian rhythm. Production of melatonine
is stimulated by darkness and inhibited by light. Patients
admitted to the ICU develop impaired sleep patterns.
Factors which contribute to the sleep impairment in-
clude the use of opioids and benzodiazepines, which dis-
rupt rapid eye movement (REM), the impact of specific
patient therapies such as asynchrony to mechanical
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ities, environmental noise, and non-phasic light exposure
[33]. Lower levels of melatonine and disrupted circadian
release of melatonine have been associated with ICU
delirium [34].
Why it is important to do this overview
In the critically ill patients, 40 to 89% are reported to be
affected by delirium and poor clinical outcomes are as-
sociated with the syndrome [9, 35–38]. Delirium patients
may experience functional decline and long-term cogni-
tive impairment [39–41]. Furthermore, delirium is asso-
ciated with increased morbidity, lengthened duration of
mechanical ventilation, ICU and hospital lengths of stay,
and mortality [12, 14, 36, 39–43].
The economic burden of delirium is significant [44].
In hospitals, ICU beds are expensive, and some coun-
tries spend 0.7% of the national gross product on inten-
sive care [44]. Due to an aging population and the
increasingly advanced medical and surgical care, the
number of patients in need of intensive care is expected
to increase in the coming years [45].
The evidence on the effects of pharmaceutical
interventions
A number of trials investigating pharmacological preven-
tion or management options have been published. How-
ever, uncertainty regarding the benefits and harms of
pharmacological interventions, remains considerable,
and trials have shown either positive [46, 47], equipoise
[48, 49], or negative results [50].
Trials investigating the effects of antipsychotics
(quetiapine, ziprazidone, risperiodene, haloperidol) have
been conducted [46, 48, 51, 52]. The use of antipsy-
chotics is associated with neurological side effects, in-
cluding the development of extrapyramidal side effects,
tardive dyskinesia, and neuroleptic malignant syndrome
[1]. Management of delirium with haloperidol has been
found to lengthen the QT interval, which can lead to
torsades de pointes tachycardia that can degenerate to
ventricular fibrillation and sudden death [53].
No sedative agent has been reported to improve sur-
vival in randomised clinical trials, despite at least 90 tri-
als comparing sedative regimens in a systematic review
[54]. In another meta-analysis comparing propofol to
any sedative agent, propofol did not show to reduce
mortality but may result in a reduction in the length of
stay in the ICU when compared to benzodiazepines, but
not when compared to midazolam [55]. Dexmedetomi-
dine may have advantages compared with benzodiaze-
pines, since it produces analgesia, causes less respiratory
distress, and provides a different type of sedation in
which patients are more interactive and so their needs are
potentially easier communicated [56]. Dexmedetomidinecompared to lorazepam and midazolam in randomised
clinical trials has been shown to result in less delirium and
a shorter duration of mechanical ventilation [56–58].
Morphine has been compared with haloperidol in the
management of hyperactive delirium and was found to
have a quick beneficial effect and no adverse effects [59].
Ketamine has been compared to placebo in the preven-
tion of delirium and was found to lower the incidence of
delirium [60].
Rivastigmine has in one trial been compared to pla-
cebo for the management of delirium, as an adjunct to
usual care based on haloperidol. The trial was stopped
early due to increased mortality in the rivastigmine
group; thus, rivastigmine is not recommended to man-
age delirium in the ICU [50].
Objectives
The objective of this overview of all reviews and meta-
analyses is to critically assess the evidence of reviews on
the effects of pharmacological management and preven-
tion of delirium in intensive care patients.
Methods
This protocol was written in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols checklist (Additional file 1).
Systematic review methods will follow the principles
outlined in the Cochrane Handbook [61] and the recom-
mendations given by Robinson et al. [62].
The protocol is registered on the PROSPERO database
(CRD42016046628).
Criteria for considering reviews for inclusion
All reviews and meta-analyses of pharmacological inter-
ventions for managing or preventing delirium in ICU pa-
tients that fulfil the following criteria will be eligible for
inclusion:
Types of studies
We will include all reviews and meta-analyses. We will
define a systematic review as a review positively fulfilling
the checklist in Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [63].
Participants
We will include ICU patients defined as patients treated
in an ICU of any specialty (e.g. medical, surgical, trauma,
cardiac) or similar terms according to definitions applied
by the review authors. We will include reviews of any
ICU patients equal to 18 years or older. In addition, we
will include elective cardiac surgical population and
acutely operated patients.
Reviews on the following patients will be excluded: ICU
patients with delirium caused by alcohol withdrawal,
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gency care department, and elective surgical patients
in general.
Reviews including ICU patients as well as other pa-
tient groups are eligible for inclusion if the ICU patients
are described or analysed separately or the results/tables
are given separately for this group of patients. In
addition, if a review has included both randomised clin-
ical trials and observational studies, the systematic re-
view will only be eligible for inclusion in the analysis if
the results of the randomised clinical trials are presented
separately.
Interventions
All pharmacological interventions both for the manage-
ment and the prevention of delirium will be accepted.
We will accept all reviews comparing a pharmacological
agent with the following: placebo, any other pharmaco-
logical agent, or combinations of pharmacological and
non-pharmacological interventions (bundle). Comple-
mentary therapies are eligible for inclusion too. We will
also accept reviews if they are just describing pharmaco-
logical agents or combinations of these.
Outcomes of interest
Results on all primary and secondary outcomes of the
included systematic reviews will be reported. However,
we will define primary and secondary outcomes for this
overview as follows:
Primary outcomes
1. All-cause mortality
2. Proportion of participants with a serious adverse
event defined as any untoward medical occurrence
that resulted in death, was life threatening, was
persistent, led to significant disability, jeopardised
the participant, led to hospitalisation, or prolonged
hospitalisation [64]
3. Proportion of participants with resolution of delirium
symptom at end of treatment (as defined by review
authors) (RR) and proportion of participants with
delirium despite the administration of pharmacological
drug before diagnosing delirium (prevention) (RR)
Secondary outcomes
1. Quality of life at end of treatment (any valid
continuous quality of life scale used by the review
authors)
2. Proportion of participants with non-serious adverse
events, defined as any non-serious adverse event.
Each adverse event will be analysed separately.
3. Cognitive function (any valid continuous cognitive
function scale used by the review authors)Exploratory outcomes
1. Duration of ICU stay
2. Duration of mechanical ventilation
The assessment time point of primary interest will be
the time point closest to 3 months after randomisation.
We will secondly assess each outcome at maximum
follow-up.
Search methods for identification of reviews
Electronic searches
Reviews that fulfil the inclusions criteria will be identi-
fied through literature searching specific designed to
identify relevant reviews.
The following databases will be searched:
 Cochrane Library
 MEDLINE (OvidSP)
 EMBASE (OvidSP)
 Science Citation Index-Expanded (Web of Science)
 BIOSIS Previews (Web of Science)
 Cumulative Index to Nursing and Allied Health
Literature (CINAHL)
 Latin American Caribbean Health Sciences
Literature (LILACS)
 Allied and Complementary Medicine Database
(AMED) (Additional file 2)
Searching other sources
Reference lists of reviews, relevant papers, randomised
and non-randomised trials as well as editorials will be
screened manually for potentially includable reviews.
Data collection and analysis
The following methods on data collection and data ana-
lyses will be used.
Selection of reviews
Two authors (MB, LKL/MO) will independently screen
the titles and abstracts of all reports identified by the
searches using the systematic review management toll
Covidence [65]. Reports which are deemed potentially
relevant by any of the reviewers will be obtained in full
text, and the same two reviewers will independently as-
sess these for inclusion. Any disagreement will be re-
solved by consensus.
Data extraction and management
Two authors (MB, LKL/MO) will independently extract
predefined data of the included reviews using a data
extraction form (Additional file 3) which is specifically
designed and piloted by the review team. Any disagree-
ment concerning the extracted data will be discussed
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can be reached, a third author (JCJ/JW) will resolve the
issue. Whenever necessary, corresponding authors will
be contacted to clarify issues related to data reporting or
if further review details are needed.
Assessment of methodological quality of included
reviews
The methodological quality of the included reviews will
be assessed independently by two authors (MB, LKL/
MO). First, all reviews will be checked against the
PRISMA statements [63]. Hereafter, we will assess the
methodological quality of the reviews fulfilling the
PRISMA statements using the ROBIS tool [66]. Dis-
agreements concerning the methodological assessment
will be discussed between the authors and a third author
(JCJ/JW) will be involved if no agreement can be
reached.
We will assess risk of bias by assessing four domains,
which cover key review processes: study eligibility cri-
teria, identification and selection of studies, data collec-
tion and study appraisal, and synthesis and findings.
Each domain will be assessed for information used to
support the judgement, signalling questions, and judge-
ment of concern about risk of bias. The signalling ques-
tions will be answered “Yes”, “Probably Yes”, “Probably
No”, “No” and “No Information”, with “Yes” indicating
low concerns. Hereafter each bias domain is judged as
“Low”, “High”, or “Unclear”. For a domain to be judged
low level of concern, then all signalling questions for the
domain are Yes or Probably Yes. Concern about bias will
be raised if any signalling questions is answered “No” or
“Probably No” [67].
The non-systematic reviews will be assessed as high
risk of bias notwithstanding that the methodological
quality of these may not be low according to other
standards.
Our conclusions will primarily be based on the sys-
tematic reviews assessed with low risk of bias according
to ROBIS [66].
Data synthesis
We will categorise reviews into the following:
1. Systematic reviews according to PRISMA with low
risk of bias assessed with ROBIS
2. Systematic reviews according to PRISMA with high
risk of bias assessed with ROBIS
3. Non-systematic reviews according to PRISMA
We will present the data as a narrative synthesis and
summarise the main results of the included reviews. In
addition, we will present an overview of the bias risk as-
sessment of the assessed systematic reviews.For systematic reviews deemed to be low risk of bias,
we will reassess risk of bias in the included trials. For
each identified intervention we will, if possible, perform
meta-analysis and trial sequential analysis [68] of the
low risk of bias trials.
Assessment of risk of bias of studies included in
systematic reviews deemed to be low risk of bias
MB and LKL/MO will independently assess the meth-
odological quality of each included trial, defined by the
design of the trial and reporting. Any disagreement will
be discussed between the authors. We will assess the
risk of bias according to the Cochrane Handbook of
Systematic Reviews of Interventions [61].
For all included trials, we will assess the following risk
of bias domains: random sequence generation, allocation
sequence concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting, other bias
risk and overall risk of bias. Based on this assessment,
the included trials and each outcome result will be de-
fined as low risk of bias if all bias domains are judged as
low risk of bias.
Classification will be made according to the domains
below:
Random sequence generation
 Low risk: If sequence generation is achieved using
computer, random number generator or a random
numbers table. Drawing lots, tossing a coin, shuffling
cards and throwing dice are also being considered
adequate if performed by an independent adjudicator.
 Unclear risk: If the method of randomization is not
specified.
 High risk: If the allocation sequence is not random.
Allocation sequence concealment
 Low risk: If the allocation of patients is performed by
a central independent unit, on-site locked computer,
identically looking numbered sealed opaque
envelopes, and drug bottles or containers prepared by
an independent investigator. There must be no risk of
the investigator knowing the sequence.
 Unclear risk: If the trial is classified as randomised but
the allocation concealment process is not described.
 High risk: If the allocation sequence is known to the
investigators who assigned participants.
Blinding of participants and personnel
 Low risk: If the participants and the personnel are
blinded to treatment allocation and this is described.
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insufficiently described or not described at all.
 High risk: If blinding of participants and personnel is
not performed.
Blinding of outcome assessment
 Low risk: If the trial investigators performing the
outcome assessments, analyses and calculations are
blinded to the intervention.
 Unclear risk: If the procedure of blinding is
insufficiently described or not described at all.
 High risk: If blinding of outcome assessment is not
performed.
Incomplete outcome data
 Low risk: (1) There are no dropouts or withdrawals
for all outcomes or (2) the numbers and reasons for
the withdrawals and dropouts for all outcomes are
clearly stated and can be described as being similar
in both groups. As a general rule, the trial is judged
as at a low risk of bias due to incomplete outcome
data if the number of dropouts is less than 5%.
However, the 5% cut off is not definitive.
 Unclear risk: The numbers and reasons for
withdrawals and dropouts are not clearly stated.
 High risk: The pattern of dropouts can be described
as being different in the two intervention groups or
the trial uses improper methodology in dealing
with the missing data, e.g. last observation carried
forward.
Selective outcome reporting
 Low risk: A protocol is published before or at the
time the trial is begun, and the outcome called for
in the protocol is reported on.
 Unclear risk: If there is no protocol and the outcome
is not reported on.
 High risk: If the outcomes which are called on in a
protocol are not reported on.
Other bias risk
 Low risk of bias: The trial appears to be free of other
components (for example, academic bias or for-profit
bias) that could put it at risk of bias.
 Unclear risk of bias: The trial may or may not be free
of other components that could put it at risk of bias.
 High risk of bias: There are other factors in the trial
that could put it at risk of bias (for example, authors
have conducted trials on the same topic, for-profit
bias)Overall risk of bias
We will classify all trials as follows:
 Overall low risk of bias: The trial will be classified as
overall “low risk of bias” only if all of the bias
domains described in the above paragraphs are
classified as “low risk of bias”.
 Overall high risk of bias: The trial will be classified
“high risk of bias” if any of the bias risk domains
described in the above are classified as “unclear” or
“high risk of bias”.
In addition, we will assess the domains “Blinding of
outcome assessment”, “Incomplete outcome data”, and
“Selective outcome reporting” for each outcome.
Thus, we will be able to assess the bias risk for each
result.
We will prepare a summary assessment of the risk of
bias across trials and for each important outcome
(across domains) by preparing a “Risk of bias graph” and
a “Risk of bias summary figure” [61].
Measures of treatment effect
Risk ratio (RR) with 95% confidence interval (Cl) and
TSA adjusted CI will be calculated for dichotomous out-
comes. For continuous outcomes, both end-scores and
change scores will be included in the analyses. End-
scores will be used if both are reported. Mean difference
(MD) and standardised mean difference (SMD) with
95% Cls and TSA adjusted Cls will be calculated for con-
tinuous outcomes.
We have defined three co-primary outcomes and three
secondary outcomes; thus, we will also report Cl’s as Cl
97.5%.
Unit of analysis issues
We will only include participants according to the treat-
ment group of the randomised clinical trials, therefore,
no unit of analysis issues.
Dealing with missing data
We will contact trial investigators of the original report
for important missing data.
For both dichotomous and continuous outcomes,
we will not be imputing missing data for any out-
comes in the primary analysis and intention-to-treat
data will not be used if the original report did not
contain such data.
If standard deviations (SD) are not reported, the SDs
will be calculated using data from the trial if possible.
In the sensitivity analysis for dichotomous and con-
tinuous outcomes, imputed data will be used, see
“Sensitivity analysis”.
Barbateskovic et al. Systematic Reviews  (2016) 5:211 Page 8 of 12Assessment of heterogeneity
We will assess signs of heterogeneity by visual inspec-
tion of the forest plots.
We will assess presence of statistical heterogeneity by
chi-squared test with significance set at P < 0.10 and by
measuring the quantities of heterogeneity by I2 statistic
[69]. We will consider I2 of 40% or higher as substantial
heterogeneity.
We will explore potential clinical heterogeneity by
conducting the prespecified subgroup analyses, see
“Subgroup analysis and investigation of heterogeneity”.
Assessment of reporting biases
We will visually assess funnel plots for signs of asymmetry
if 10 or more trials are included in an analysis [61, 70].
We will test asymmetry within dichotomous outcomes
with the Harbord test [71] and for continuous outcomes
regression asymmetry test [72]. Adjusted rank correl-
ation will be used [73].
Data synthesis
Meta-analysis
We will perform meta-analysis of outcomes with com-
parable effect measures where more than one trial is in-
cluded. We will not meta-analyse trials if the clinical
heterogeneity is substantial. The statistical software
Review Manager [74] provided by the Cochrane
Collaboration and the TSA [75] software ver. 0.9
CTU will be used to meta-analyse data.
Assessment of significance
We will assess our intervention effects with both
random-effects model meta-analyses (67–69) and fixed-
effect model meta-analyses [76, 77]. Anticipating large
clinical as well as statistical heterogeneity, we will gener-
ally prefer reporting the result from a random-effects
model. However, if one or two trials dominate the ac-
quired evidence (e.g. with more than 80% of the rando-
mised patients [78–80] the random-effects model may
grossly overestimate the intervention effect and in this
situation, we will report primarily the result from the
fixed-effect model. That is, we will primarily report the
result from the model with the most conservative point
estimate of the two [70], being the estimate closest to
zero effect. If the two estimates are approximately equal,
we will use the estimate with the widest CI.
We use three primary outcomes and, therefore, we will
consider a P value of 0.025 or less as statistically signifi-
cant analysing the primary outcomes [70, 81]. We use
three secondary outcomes and, therefore, we will con-
sider a P value of 0.025 or less as statistically significant
analysing the secondary outcomes [70]. We will use the
eight-step procedure to assess if the thresholds for sig-
nificance are crossed [70].Trial sequential analysis
Cumulative meta-analyses are at risk of producing ran-
dom errors due to sparse data and multiple testing of ac-
cumulating data [68, 82–89]; therefore, TSA [75] can be
applied to assess this risk [90]. The required information
size and the required number of trials [91] (which is the
number of participants and trials needed in a meta-
analysis to detect or reject an a priori prespecified realis-
tic intervention effect) can be calculated in order to
minimise random errors [92]. The required information
size takes into account the event proportion in the con-
trol group, the assumption of a plausible relative risk
(RR) reduction, and the heterogeneity variance [93] of
the meta-analysis [92]. TSA enables testing for signifi-
cance to be conducted each time a new trial is included
in the meta-analysis. On the basis of the required infor-
mation size and the required number of trials, trial se-
quential monitoring boundaries can be constructed. This
enables one to determine the statistical inference con-
cerning cumulative meta-analysis that has not yet
reached the required information size [68, 85, 86, 88].
Firm evidence for benefit or harms may be established
if the trial sequential monitoring boundary is crossed be-
fore reaching the required information size; in which
case, further trials may turn out to be superfluous. In
contrast, if the boundary is not surpassed, one may con-
clude that it is necessary to continue with further trials
before a certain intervention effect can be detected or
rejected. Firm evidence for lack of the postulated inter-
vention effect can also be assessed with TSA. This oc-
curs when the cumulative Z-score crosses the trial
sequential monitoring boundaries for futility.
We will use relatively conservative estimations of the
anticipated intervention effect estimates to reduce the
risk of random error [70]. Large anticipated intervention
effects lead to small required information sizes and the
thresholds for significance will be less strict after the in-
formation size has been reached [70].
We will analyse all primary and secondary outcomes
with TSA. We will estimate the diversity-adjusted required
information size [92] based on the proportion of patients
with an outcome in the control group. In addition, we will
use a family-wise error rate (FWER) of 5% [70] leading to
a statistical significance level of 3.3% for each of the co-
primary outcomes, a beta of 20%, and a diversity (D2) [92]
suggested by the trials in the meta-analysis [70]. As a sen-
sitivity analysis, we will use a diversity of 20% if the actual
measured heterogeneity is in fact zero because in this case
heterogeneity will most likely increase when further trials
are added until the required information size is reached.
As anticipated intervention effects for the primary and
secondary outcomes in the trial sequential analysis, we
will use realistic a priori relative risk reductions (RRR) or
increases of 20% RRR or a 20% relative risk increase (RRI).
Barbateskovic et al. Systematic Reviews  (2016) 5:211 Page 9 of 12Furthermore, we will use a RRR or a RRI based on the
confidence limit closest to null effect in the 96.7% Cl in
the traditional meta-analysis.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be performed to seek to deter-
mine if the efficacy and safety of the treatment options
are influenced by the types of ICU populations.
The following subgroup analyses will be conducted if
data permit:
 Trials with overall high risk of bias compared to
trials with overall low or uncertain risk of bias
According to population
 Medical patients
 Surgical patients
 Cardiac surgical patients
 Acutely operated patients
Sensitivity analysis
To assess the potential impact of bias, a sensitivity ana-
lysis for each outcome will be performed where trials
with overall “high risk of bias” will be excluded.
To assess the potential impact of the missing data for
dichotomous outcomes, the two following analyses will
be performed:
1. “Best-worst-case” scenario: It will be assumed that all
participants lost to follow-up in the experimental
group survived, had no serious adverse event, and had
no morbidity; and all those with missing outcomes in
the control group did not survive, had a serious
adverse event, and had morbidity.
2. “Worst-best-case” scenario: It will be assumed that
all participants lost to follow-up in the experimental
group did not survive, had a serious adverse event,
and had morbidity; and all those with missing
outcomes in the control group did survive, had
no serious adverse event, and had no morbidity.
Results from both scenarios will be presented in the
review.
To assess the potential impact of the missing data for
continuous outcomes, the two following analyses will be
performed:
1. “Best-worst-case” scenario: It will be assumed that all
participants lost to follow-up in the experimental
group had mean (from patients with follow-up) +
2 × SD; and all those with missing outcomes in
the control group had mean (from patients with
follow-up) − 2 × SD [70].2. “Worst-best-case” scenario: It will be assumed that
all participants lost to follow-up in the experimental
group had mean (from patients with follow-up) −
2 × SD; and all those with missing outcomes in the
control group had mean (from patients with
follow-up) + 2 × SD [70].
To assess the potential impact of missing SDs for
continuous outcomes, the following sensitivity
analyses will be performed: where SDs are missing
and not possible to calculate, SDs will be imputed
from trials with similar populations and low risk of
bias. If no such trials can be found, SDs will be
imputed from the trials with a similar population. As
the final option, SDs will be imputed from all the
trials.
Summary of findings
We will present our findings in tables categorising re-
views into (1) systematic reviews according to PRISMA
with low risk of bias assessed with ROBIS, (2) systematic
reviews according to PRISMA with high risk of bias
assessed with ROBIS, and (3) non-systematic reviews ac-
cording to PRISMA.
We will use the GRADE system [94] to assess the
quality of the body of evidence identified from system-
atic reviews with low risk of bias associated with each of
the primary outcomes (all-cause mortality, serious adverse
events, resolution of delirium (treatment)/incidence
(preventon)) and secondary outcomes (quality of life,
non-serious adverse events, cognitive function) by
constructing summary of findings (SoF) tables using
the GRADE software [95]. For each primary and sec-
ondary outcome, firstly, we will present the summary
of findings in randomised clinical trials with overall
low risk of bias and, secondarily, the results in all the
trials.
The GRADE approach appraises the quality of a body
of evidence based on the extent to which one can be
confident that an estimate of effect or association re-
flects the item being assessed. The quality measure of a
body of evidence considers within the study risk of bias,
the directness of the evidence, heterogeneity of the data,
precision of effect estimates [70], and risk of publication
bias.
We will include all risk of bias in the SOF table and
then downgrade the quality of the evidence to take the
bias into account.
Discussion
To our knowledge, no overview summarising the best
available evidence of pharmacological interventions
against delirium in the ICU has been published. Our sys-
tematic and comprehensive literature search is targeted
to identify all published reviews and meta-analyses, and
Barbateskovic et al. Systematic Reviews  (2016) 5:211 Page 10 of 12we aim to summarise the evidence based primarily on
systematic reviews with low risk of bias. We define
systematic reviews according to PRISMA [63] and low
risk of bias according to ROBIS. This choice may
limit the number of systematic reviews on which to
base our conclusions, but at the same time, this is a
strength as we are thus purporting only the best
available evidence. The result of our review will de-
fine the need for a new high quality systematic
review.
A preliminary search identified several reviews
[28, 96–105] investigating the effects of pharmaco-
logical interventions for the management and pre-
vention of delirium in the critically ill, of which
some reveals conflicting results. E.g. Lacasse et al.
[96] suggests that antipsychotic drugs are efficacious
and safe for the management of delirium, while Ser-
afim et al. [105] did not find an association between
pharmacologic management and delirium duration.
However, Serafim et al. [105] do suggest antipsy-
chotics for surgical ICU patients and dexmedetomi-
dine for mechanically ventilated patients as a
preventive strategy.
Despite the conflicting and inconclusive results in
supporting the use of pharmacological agents in the
management of delirium, antipsychotics and, in par-
ticular, haloperidol remains the intervention recom-
mended as drugs of first choice, even though the
latest guideline states that no published evidence is
in support of managing delirious critically ill pa-
tients, nor for prevention of delirium, with haloperi-
dol [21].
We consider it important to perform an overview of
reviews summarising systematically and critically the
available evidence from reviews of randomised clinical
trials on pharmacological interventions in managing and
preventing delirium in the ICU patients. Based on this
overview of reviews, it will be possible to update or to
design a high quality systematic review and, subse-
quently, a high quality randomised clinical trial, of the
most promising candidate for pharmacological interven-
tion for managing (or preventing) delirium in the ICU
patient. Identifying the most effective intervention for
delirium in critically ill patients will benefit patients,
healthcare systems, and healthcare economy throughout
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